Adoptive T-Cell Therapy against Solid Tumors
A special issue of Immuno (ISSN 2673-5601).
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 19212
Special Issue Editor
Interests: CAR-T cells; melanoma; adoptive cell therapy; cancer vaccination; cancer immunotherapy; solid tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumor-antigen-specific cytotoxic T lymphocytes (CTL) play a key role in tumor immunology. Therefore, the generation of these cells to support the often-crippled immune system of the patient has been the main aim in the cellular adoptive immunotherapy of cancer. The transferred cells range from tumor-infiltrating lymphocytes (TIL) to T cells reprogrammed with a tumor-antigen specificity by transfer of a T-cell receptor (TCR) or chimeric antigen receptor (CAR). The latter strategy in particular has proven to be very efficient in the treatment of hematologic tumors. However, the efficacy against solid tumor lags behind. Therefore, this Special Issue will focus on improvements and new strategies of adoptive T-cell therapy against solid tumors.
Immuno is a new international, peer-reviewed scientific open-access journal that provides an advanced forum for studies related to basic and clinical immunology research published quarterly online by MDPI.
Authors are cordially invited to contribute original research papers or reviews to this Special Issue of Immuno.
Prof. Dr. Niels Schaft
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Solid tumor
- TIL
- TCR transfer
- CAR-T cells
- Tumor microenvironment
- CAR format
- Targeted antigens
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
